Medicare will cover semaglutide (Wegovy) and tirzepatide (Zepbound) for their weight management indications for people with ...

Intensifying competition, pricing pressure and copycat versions of Ozempic and Wegovy hold back sales at the pharma giant.

Novo Nordisk and Eli Lilly said they've agreed to sell their blockbuster drugs Wegovy and Zepbound at a discount.

Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have ...

The US Food and Drug Administration (FDA) has approved Linzess (linaclotide) as the first treatment for children living with ...

Eli Lilly and Novo Nordisk agree to expand access and cut prices for Zepbound and Wegovy • Medicare to begin covering obesity ...

The agreements with pharma giants Eli Lilly and Novo Nordisk could bring the price of the GLP-1 injectables from roughly ...

The drugmaker said it would launch late-stage trials of the drug after participants lost as much as 20% of their body weight.

Medicare beneficiaries will soon be able to get obesity and Type 2 diabetes drugs for a $50 copay. But there are some ...

President Trump wants pharmaceutical production to return to the United States. A shuttered factory in Louisiana shows how ...

Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight ...

Both Lilly and Novo are racing to bring oral versions of their blockbuster GLP-1 treatments to market. Novo's once-daily oral ...